Price T Rowe Associates Inc Aldeyra Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 48,473 shares of ALDX stock, worth $261,754. This represents 0.0% of its overall portfolio holdings.
Number of Shares
48,473
Previous 48,273
0.41%
Holding current value
$261,754
Previous $158,000
1.9%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ALDX
# of Institutions
107Shares Held
35.3MCall Options Held
153KPut Options Held
83.9K-
Perceptive Advisors LLC New York, NY9.28MShares$50.1 Million0.89% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$29.6 Million12.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.74MShares$20.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$19.6 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.6MShares$8.64 Million0.12% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $315M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...